Global Tardive Dyskinesia Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

SKU ID : GIR-GIR1810160453 12542209

Publishing Date : 06-Nov-2018

No. of pages : 101

PRICE
3480
6960


  • Tardive Dyskinesia (TD) market is estimated to post significant growth in coming years, owing to rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription and increasing incidence of neurological disorders.



    Scope of the Report:

    This report studies the Tardive Dyskinesia market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Tardive Dyskinesia market by product type and applications/end industries.

    The key factors driving the growth of the Tardive dyskinesia market are rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription, increased use of long-term neuroleptic drugs and increasing incidence of neurological disorders. However, the expansion of the market is hindered by side effects of drugs and under-diagnosed.

    The global Tardive Dyskinesia market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

    The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

    North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Tardive Dyskinesia.

    Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.



    Market Segment by Companies, this report covers

    Valeant Pharmaceuticals

    Neurocrine Biosciences

    Teva Pharmaceuticals Industries



    Market Segment by Regions, regional analysis covers

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Russia and Italy)

    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

    South America (Brazil, Argentina, Colombia)

    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



    Market Segment by Type, covers

    Dopamine-Depleting Medications

    GABA Receptor Agonist Medications

    Anticholinergic Medications



    Market Segment by Applications, can be divided into

    Hospitals

    Ambulatory Surgical Centers

    Diagnostic Centers